Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center and director of the University ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.